October 25, 2012 ·
Leave a comment
Thought Leader Select is a company focused on driving industry collaborations among biopharmaceutical, medical device, and diagnostics companies with leading medical experts and centers of excellence, with the ultimate goals of these collaborations being two-fold in purpose: better treatment options for patients and better outcomes for global public health. As part of our company’s mission, we work with multiple organizations to promote best practices that deliver ethical, transparent interactions among these various healthcare constituencies.
One of these groups is the recently-launched Medical Science Liaison Society, a global Non-Profit organization being led by the Chairman of the Board, Dr. Samuel Dyer. The MSL Society is filling a vital need for the expanding role of Medical Science Liaisons around the world, as they collaborate with KOLs, physicians, and other health care professionals to advance medical science together to improve the quality of life for patients everywhere.
Thought Leader Select’s Allison Murphy, a veteran MSL herself from her days working in the Endocrinology Medical Affairs unit at Eli Lilly and Company, recently sat down with Dr. Dyer to learn more about this emerging organization and the impact the MSL Society is
having in promoting the role of Medical Science Liaisons in the pharmaceutical, biopharmaceutical, medical device, and diagnostics industries.
Allison Murphy: ... read more »
March 14, 2012 ·
Leave a comment
Industry Insights from Brian Castle
As in nearly all other aspects of life, social media is fast becoming a dominant force in the world of healthcare. Leading centers of excellence—hospitals, clinics, research foundations, and universities—are utilizing social media to educate patients about medical resources and treatments on a daily basis. Biopharmaceutical companies are using social media to promote new medications and further educate patients about other wellness resources at their disposal to help with debilitating diseases and conditions.
Physicians and other healthcare professionals, like practically every other profession, are embracing social media at unprecedented levels, engaging with each other on everything from new medical devices to tough medical cases. Due to this rise in HCP use of social media, some have begun to question the very essence of what makes a key opinion leader in the medical profession.
Some of these questioners have gone a step farther, at their ultimate peril, in misinterpreting physician involvement in spaces like Twitter, Facebook, LinkedIn and physician-only social media networks like Sermo. They incorrectly perceive that social media participation is the new thought leadership. Last year, I sat in the audience for a presentation by a leader in the pharmaceutical industry. This person posited a talking point she’d heard from an executive at a physician-only social media network: “If you’re not in their social network, you’re not ... read more »
October 28, 2011 ·
Leave a comment
Thought Leader Select is pleased to announce a pair of projects in support of a top 10 global biopharmaceutical company as it seeks to develop a portfolio of medicines in women’s health.
For the assessments, Thought Leader Select will study key opinion leaders and medical centers of excellence in the treatment of cancers affecting the gynecological health of women, specifically ovarian cancer, cervical cancer, and uterine cancer. In the first assessment, the company will identify and profile Canadian oncologists with vast expertise in research and treatment of these cancers affecting women. In the second assessment, Thought Leader Select will identify and profile Canadian medical centers with specialized infrastructures for research and treatment in these disease areas.
“We are very proud to begin this critical work supporting pharmaceutical development in the area of women’s health,” stated Neil Mellor, Thought Leader Select’s global business development consultant. “This client is an established leader in developing medicines for the treatment of various forms of cancer, and we appreciate the opportunity to help them partner with the right key opinion leaders and centers of excellence in women’s health and oncology, to ultimately help patients suffering from these cancers.”
February 28, 2011 ·
Leave a comment
Regulatory Guidance from Aprel Buonpane
The main components of the new US healthcare reform legislation will continue to be subjects for debate in the coming months and years, but tucked in among all of the changes for Medicare beneficiaries, coverage for pre-existing conditions, and the effects on small business owners lies a provision that most laypeople would not even notice. This provision, however, has the attention of US drug and device manufacturers and cannot be ignored.
The Physician Payment Sunshine Provision, also known as the Sunshine Act, requires that these companies publicly report gifts and payments made to physicians and other entities such as teaching hospitals. The intention of the provision is to address the public’s perception that biopharmaceutical companies use payments to influence a physician’s prescription-writing habits and to improve transparency as to what actually does exchange hands, in the form of services and remuneration for those services, and why. Drug and device manufacturers must begin capturing this data in January 2012 and must make their first report on these activities to the Department of Health and Human Services by March 2013. This provision has far-reaching implications for how the medical meetings and event industry will conduct its business in service of the healthcare community for years to come.
The new law requires that every dollar spent on physicians and health care ... read more »
February 9, 2011 ·
Leave a comment
Trendspotting with Kristen Smithwick
There’s been plenty of talk in recent months about the impact of social media on the future of healthcare. Many stakeholders are carving out their own space within the social media sphere, with customized strategies that fit their respective ambitions and external pressures, such as regulatory guidelines.
Biopharmaceutical companies are beginning to craft social media strategies and experiment with different activities; the FDA is reviewing potential social media guidelines; and medical professionals are individually using social media in a variety of ways. A recent article in MedAd News says that “according to Manhattan Research, 89 million American adults used social media for health in 2010”. That’s a staggering figure –nearly 30% of the American population used social media sites to discuss health-related issues. Evidence that the use of social media in healthcare is here to stay has even hit pop culture, when last week’s episode of Grey’s Anatomy featured Dr. Bailey tweeting her surgery play-by-play. Upon seeing how much visibility his department could attain within the medical community, even Chief Webber jumped on board!
At Thought Leader Select, we’re also examining how to better understand the ways that thought leaders in the medical community use social media. In our quest to stay on top of the trends among medical experts, ... read more »
December 6, 2010 ·
According to CURE Epilepsy, epilepsy affects 50,000,000 people worldwide (http://www.cureepilepsy.org/about/epilepsy_facts.asp). This disorder can be debilitating, and finding the ideal treatment can improve patients’ quality of life significantly. In addition to patient advocacy groups, health care professionals (HCPs) are often involved in advocating for the rights of individuals with epilepsy, including educating patient groups about the disorder and possible treatment options, lobbying governmental bodies for affordable healthcare and research dollars, and actively fundraising for money to find a cure. Some HCPs lead their peers in advancing medical science to understand epilepsy better and to find new therapies that will improve quality of life. These thought leaders are often highly involved in advocacy efforts.
Thought Leader Select is a firm that specializes in delivering objective, validated data on the skills and experiences of key thought leaders, so that biopharmaceutical companies can seek their appropriate advice and guidance in the development of new medicines. Over the past several years, Thought Leader Select has studied key opinion leaders (KOLs) in the treatment of epilepsy and their involvement in many areas, including clinical research, treatment guidelines involvement, publishing, reimbursement involvement and participation in advocacy efforts. In a recent assessment of over 200 global epilepsy KOLs, Thought Leader Select analyzed their participation in patient advocacy ... read more »